Please login to the form below

Not currently logged in
Email:
Password:

Indian court rejects Novartis patent demand

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

Novartis was demanding that India grant a patent for Glivec to prevent cheap copies being made. The government in New Delhi opposed the move, saying that granting such a patent would violate India's patent legislation.

Novartis has been seeking a patent for Glivec in India, challenging the Indian patent law which currently does not protect incremental innovation. Indian law does not grant patents for modifications to old medicines, but only to properly innovative drugs developed after 1995.

6th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics